AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28559255 — intervention group
Group type: EXPERIMENTAL
Intervention: MHAB5553A (1,200 mg)
Number of subjects: 26
Study 28559255 — intervention group
Group type: EXPERIMENTAL
Intervention: MHAB5553A (3,600 mg)
Number of subjects: 26
Study 28559255 — intervention group
Group type: EXPERIMENTAL
Intervention: MHAB5553A (8,400 mg)
Number of subjects: 26
Study 28559255 — intervention group
Group type: EXPERIMENTAL
Intervention: MHAB5553A (10,800 mg)
Number of subjects: 26
Study 28559255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 28559255 — intervention group
Group type: EXPERIMENTAL
Intervention: MHAB5553A
Number of subjects: 26
Study 25062086 — intervention group
Group type: EXPERIMENTAL
Intervention: Myorelaxation Therapy (nocturnally applied non-occluding sublingual relaxation splint combined with daily stretching exercises)
Number of subjects: 78
Study 25062086 — intervention group
Group type: COMPARATOR
Intervention: Control period (no interventions for 4 weeks)
Number of subjects: 78
Study 23948337 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-supported agriculture (CSA) intervention with 5 educational sessions and a box of fresh produce for 16 weeks
Number of subjects: 50
Study 23948337 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational sessions or produce delivery)
Number of subjects: 50
Study 21774822 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg daily; n = 28)
Number of subjects: 60
Study 21774822 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 32)
Number of subjects: 60
Study 19294756 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trials with adequate generation of the allocation sequence
Number of subjects: 105
Study 19294756 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trials with adequate allocation concealment
Number of subjects: 105
Study 19294756 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trials that were double-blind
Number of subjects: 105
Study 19294756 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trials with adequate sample size calculation
Number of subjects: 105
Study 19294756 — intervention group
Group type: COMPARATOR
Intervention: Historical cohorts for comparison
Number of subjects: 105
Study 16407883 — intervention group
Group type: COMPARATOR
Intervention: Constant TMP at around 300 mmHg
Number of subjects: 12
Study 16407883 — intervention group
Group type: EXPERIMENTAL
Intervention: Profiled TMP (slowly increased from low to maximal value)
Number of subjects: 12
Study 12568942 — intervention group
Group type: EXPERIMENTAL
Intervention: Effort coping
Number of subjects: 40
Study 12568942 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress coping
Number of subjects: 40
Study 12568942 — intervention group
Group type: EXPERIMENTAL
Intervention: Effort-distress coping
Number of subjects: 40
Study 12568942 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 10563276 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (0.3 cc metaproterenol in 2.5 cc of saline at times 0, 20", 40", 1', 2', 3', 4', 5', 6', and 7')
Number of subjects: 71
Study 10563276 — intervention group
Group type: COMPARATOR
Intervention: Control group (metaproterenol at times 0, 1 hr, and hours 3, 5, and 7; placebo at 20", 40", 2', 4', and 6')
Number of subjects: 71
Study 8939269 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with a solution of purified and biologically standardized extract of Parietaria judaica, following a preseasonal rush schedule.
Number of subjects: 40
Study 8939269 — intervention group
Group type: COMPARATOR
Intervention: Control group (symptomatic drugs only)
Number of subjects: 40
Study 1767322 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (15 ml of the drug in 200 ml of a 0.85% NaCl solution: 10 ml in the morning and 5 ml in the evening)
Number of subjects: 60
Study 1767322 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same amount of solution as cerebrolysin)
Number of subjects: 60
Study 6979980 — intervention group
Group type: EXPERIMENTAL
Intervention: Long interview (4 to 11 minutes)
Number of subjects: 60
Study 6979980 — intervention group
Group type: COMPARATOR
Intervention: Short interview (2 minutes)
Number of subjects: 60
Study 30848023 — intervention group
Group type: EXPERIMENTAL
Intervention: McGRATH MAC videolaryngoscope
Number of subjects: 90
Study 30848023 — intervention group
Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope
Number of subjects: 90
Study 28323158 — intervention group
Group type: EXPERIMENTAL
Intervention: End-tidal sevoflurane concentration group (E)
Number of subjects: 2500
Study 28323158 — intervention group
Group type: COMPARATOR
Intervention: Routine care group (R)
Number of subjects: 2500
Study 25488963 — intervention group
Group type: EXPERIMENTAL
Intervention: Linifanib 17.5 mg once daily
Number of subjects: 1035
Study 25488963 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib 400 mg twice daily
Number of subjects: 1035
Study 23274057 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-medical prescription stimulants (NMPS)
Number of subjects: 4090
Study 23274057 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-medical prescription stimulants (NMPS) with alcohol
Number of subjects: 4090
Study 23274057 — intervention group
Group type: COMPARATOR
Intervention: Past year drinkers who did not use prescription stimulants
Number of subjects: 4090
Study 23274057 — intervention group
Group type: COMPARATOR
Intervention: Concurrent NMPS and alcohol users (use over the past year but not at the same time)
Number of subjects: 4090
Study 21469915 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) for up to 15 months
Number of subjects: 422
Study 21469915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study 17964655 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 607
Study 17964655 — intervention group
Group type: COMPARATOR
Intervention: Medications
Number of subjects: 607
Study 17964655 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (nonsmokers)
Number of subjects: 607
Study 17964655 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (smokers)
Number of subjects: 607
Study 17067837 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 23
Study 17067837 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy age-matched women)
Number of subjects: 23
Study 13680313 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 45
Study 13680313 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 45
Study 13680313 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 45
Study 13680313 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 45
Study 13680313 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathormone (PTH)
Number of subjects: 45
Study 13680313 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol, fluoride, calcium, clodronate, etidronate, hormone replacement therapy, pamidronate, strontium, tiludronate, vitamin D
Number of subjects: 45
Study 10832513 — intervention group
Group type: EXPERIMENTAL
Intervention: Current and previous users of MDMA
Number of subjects: 0
Study 10832513 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous users of MDMA
Number of subjects: 0
Study 10832513 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-users of MDMA)
Number of subjects: 0
Study 9621491 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine as a single agent
Number of subjects: 0
Study 9621491 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine combined with cisplatin
Number of subjects: 0
Study 9621491 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine combined with mitomycin C
Number of subjects: 0
Study 9621491 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine combined with 5-fluorouracil
Number of subjects: 0
Study 9621491 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine combined with ifosfamide
Number of subjects: 0
Study 9621491 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine combined with taxol
Number of subjects: 0
Study 9621491 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine combined with taxotere
Number of subjects: 0
Study 9621491 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine combined with mitoxantrone
Number of subjects: 0
Study 9621491 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine combined with doxorubicin
Number of subjects: 0
Study 9621491 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine combined with epirubicin
Number of subjects: 0
Study 8160227 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke rehabilitation unit (n = 73)
Number of subjects: 146
Study 8160227 — intervention group
Group type: COMPARATOR
Intervention: General wards (n = 68)
Number of subjects: 146
Study 8160227 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke rehabilitation unit
Number of subjects: 146
Study 8160227 — intervention group
Group type: COMPARATOR
Intervention: General wards
Number of subjects: 146
Study 3341527 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial ileal bypass surgery
Number of subjects: 189
Study 31378923 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancellous allograft and d‐PTFE membrane at 2 months
Number of subjects: 49
Study 31378923 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancellous allograft and d‐PTFE membrane at 4 months
Number of subjects: 49
Study 31378923 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancellous allograft and d‐PTFE membrane at 6 months
Number of subjects: 49
Study 29450731 — intervention group
Group type: EXPERIMENTAL
Intervention: mini-PCNL using 16.5 Fr percutaneous sheath
Number of subjects: 108
Study 29450731 — intervention group
Group type: COMPARATOR
Intervention: ESWL using Dornier Compact Sigma
Number of subjects: 108
Study 28394781 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tPCS with bimastoid montage
Number of subjects: 20
Study 28394781 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tPCS with ear-clip montage
Number of subjects: 20
Study 25779885 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cefazolin (237 patients, 60.0%)
Number of subjects: 395
Study 25779885 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic antibiotics (158 patients, 40.0%)
Number of subjects: 395
Study 23821974 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10/5/5 mg (immediately postoperatively and on day 1 and 2)
Number of subjects: 62
Study 23821974 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 20/10/10 mg
Number of subjects: 62
Study 23821974 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 62
Study 20496107 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh semen from HIV-1 patients
Number of subjects: 40
Study 20496107 — intervention group
Group type: EXPERIMENTAL
Intervention: Sperm migration after selection
Number of subjects: 40
Study 20496107 — intervention group
Group type: EXPERIMENTAL
Intervention: After freezing/thawing in HIV-1 patients
Number of subjects: 40
Study 20496107 — intervention group
Group type: COMPARATOR
Intervention: After freezing/thawing in control patients
Number of subjects: 40
Study 20496107 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh sperm in HIV-1 patients
Number of subjects: 40
Study 20496107 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen/thawed sperm in HIV-1 patients
Number of subjects: 40
Study 19099594 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 246
Study 19099594 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate plus amodiaquine (ASAQ)
Number of subjects: 246
Study 16283318 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (20 mg daily)
Number of subjects: 30
Study 16283318 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (100 mg daily)
Number of subjects: 30
Study 16283318 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy female controls)
Number of subjects: 30
Study 12169073 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 to 200 mg/d for 24 weeks)
Number of subjects: 369
Study 9800058 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized corneal topography (CCT)
Number of subjects: 50
Study 7614529 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTI‐SOAK Conditioning Solution
Number of subjects: 0
Study 7614529 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston Advance Conditioning Solution
Number of subjects: 0
Study 7614529 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston Conditioning Solution
Number of subjects: 0
Study 7614529 — intervention group
Group type: EXPERIMENTAL
Intervention: Barnes‐Hind Wetting and Soaking Solution
Number of subjects: 0
Study 7614529 — intervention group
Group type: EXPERIMENTAL
Intervention: Duracare Conditioning
Number of subjects: 0
Study 7614529 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Cleaning, Wetting & Soaking Solution
Number of subjects: 0
Study 2171596 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery + bestatin
Number of subjects: 1030
Study 2171596 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1030
Study 102114 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH) 80 mg daily for 3 weeks
Number of subjects: 6
Study 102114 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 100 mg daily for 3 weeks
Number of subjects: 6
Study 102114 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH treatment
Number of subjects: 6
Study 7035955 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 47
Study 7035955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 30869969 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic-focused psychodynamic psychotherapy (PFPP)
Number of subjects: 44
Study 29874805 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod‐PC (6 g/day of proteins from cod residuals as presscake meal)
Number of subjects: 42
Study 29874805 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod‐PCW (6 g/day of proteins from cod residuals as presscake and stickwater meal)
Number of subjects: 42
Study 29874805 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (control)
Number of subjects: 42
Study 27021752 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC) intervention
Number of subjects: 0
Study 27021752 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC) intervention
Number of subjects: 0
Study 24390777 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily school physical education (PE) for 40 minutes
Number of subjects: 2621
Study 24390777 — intervention group
Group type: COMPARATOR
Intervention: Control group with 60 minutes of PE per week
Number of subjects: 2621
Study 22071290 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (energy and protein enriched diet, oral nutritional support, calcium‐vitamin D supplement, telephone counselling by a dietician)
Number of subjects: 210
Study 22071290 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 210
Study 19602584 — intervention group
Group type: EXPERIMENTAL
Intervention: AICA-riboside infusion (2 mg x min(‐1) x dl(‐1))
Number of subjects: 24
Study 19602584 — intervention group
Group type: COMPARATOR
Intervention: AICA-riboside infusion combined with caffeine (90 microg x min(‐1) x dl(‐1); n = 6)
Number of subjects: 24
Study 19602584 — intervention group
Group type: COMPARATOR
Intervention: AICA-riboside infusion combined with l-NMMA (0.4 mg x min(‐1) x dl(‐1); n = 6)
Number of subjects: 24
Study 19602584 — intervention group
Group type: EXPERIMENTAL
Intervention: AICA-riboside infusion
Number of subjects: 24
Study 17827465 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus thoracic radiation
Number of subjects: 0
Study 17827465 — intervention group
Group type: COMPARATOR
Intervention: Thoracic radiation alone
Number of subjects: 0
Study 15924805 — intervention group
Group type: COMPARATOR
Intervention: 10 mg simvastatin
Number of subjects: 221
Study 15924805 — intervention group
Group type: COMPARATOR
Intervention: 200 mg fenofibrate
Number of subjects: 221
Study 15924805 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg simvastatin + 200 mg fenofibrate
Number of subjects: 221
Study 11895286 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP/BPBM
Number of subjects: 21
Study 11895286 — intervention group
Group type: COMPARATOR
Intervention: PRP/BPBM/GTR
Number of subjects: 21
Study 10464844 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidification (HC 100, Fischer & Paykel, Inc.)
Number of subjects: 24
Study 10464844 — intervention group
Group type: COMPARATOR
Intervention: Oily nose drops (Colda-Stop, Desitin, Inc.)
Number of subjects: 24
Study 8703644 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat 0.25 mg h‐1
Number of subjects: 45
Study 8703644 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat 0.50 mg h‐1
Number of subjects: 45
Study 8703644 — intervention group
Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 45
Study 2142054 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 20
Study 2142054 — intervention group
Group type: COMPARATOR
Intervention: Tolbutamide
Number of subjects: 20
Study 724184 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on a professional patient
Number of subjects: 0
Study 724184 — intervention group
Group type: COMPARATOR
Intervention: Training on a plastic model
Number of subjects: 0
Study 31691462 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label caplacizumab
Number of subjects: 31
Study 31691462 — intervention group
Group type: COMPARATOR
Intervention: Double-blind treatment (caplacizumab)
Number of subjects: 31
Study 31691462 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during double-blind treatment)
Number of subjects: 31
Study 31385562 — intervention group
Group type: EXPERIMENTAL
Intervention: ZuraGard (ZG)
Number of subjects: 2
Study 31385562 — intervention group
Group type: COMPARATOR
Intervention: Chloraprep (CP)
Number of subjects: 2
Study 31385562 — intervention group
Group type: COMPARATOR
Intervention: Negative control (ZV)
Number of subjects: 2
Study 28181131 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Number of subjects: 162
Study 28181131 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 162
Study 26718395 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based continuing care (TEL)
Number of subjects: 359
Study 26718395 — intervention group
Group type: COMPARATOR
Intervention: Standard continuing care (STD)
Number of subjects: 359
Study 26718395 — intervention group
Group type: COMPARATOR
Intervention: Relapse prevention (RP)
Number of subjects: 359
Study 24046466 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction catheter with a valve (Ballard Trach Care 72)
Number of subjects: 10
Study 24046466 — intervention group
Group type: COMPARATOR
Intervention: Closed suction catheter without a valve (Portex Steri‐Cath DL)
Number of subjects: 10
Study 22313580 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg depo‐methylprednisolone + 0.5% lidocaine
Number of subjects: 88
Study 22313580 — intervention group
Group type: COMPARATOR
Intervention: 0.5% lidocaine
Number of subjects: 88
Study 20018155 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroactive remote intercessory prayer for patients already dead or dismissed
Number of subjects: 36
Study 17464703 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (0.8-1.8 mg kg(‐1) day(‐1))
Number of subjects: 330
Study 17464703 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (0.2-0.6 mg kg(‐1) day(‐1))
Number of subjects: 330
Study 17464703 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 330
Study 17464703 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 330
Study 15024302 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass (LGBP)
Number of subjects: 104
Study 15024302 — intervention group
Group type: COMPARATOR
Intervention: Open gastric bypass (OGBP)
Number of subjects: 104
Study 12113380 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program (PRP) for 8 weeks including supervised incremental exercise
Number of subjects: 47
Study 12113380 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program (PRP)
Number of subjects: 47
Study 12113380 — intervention group
Group type: COMPARATOR
Intervention: Patients with cor pulmonale
Number of subjects: 47
Study 10204833 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg ascorbic acid
Number of subjects: 75
Study 10204833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 10204833 — intervention group
Group type: COMPARATOR
Intervention: 200 mg ascorbic acid
Number of subjects: 75
Study 7596492 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex ultrasonography
Number of subjects: 178
Study 7596492 — intervention group
Group type: COMPARATOR
Intervention: Conventional angiography
Number of subjects: 178
Study 2354800 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational mini-lecture series
Number of subjects: 66
Study 2354800 — intervention group
Group type: COMPARATOR
Intervention: Peer networks
Number of subjects: 66
Study 369472 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate plus haloperidol
Number of subjects: 36
Study 369472 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus haloperidol
Number of subjects: 36
Study 30009627 — intervention group
Group type: EXPERIMENTAL
Intervention: Early motion protocol (active and passive wrist motion by 14 days after surgery)
Number of subjects: 33
Study 30009627 — intervention group
Group type: COMPARATOR
Intervention: Late motion protocol (delayed motion initiated at 5 weeks)
Number of subjects: 33
Study 31821294 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone patellar tendon bone allograft (BPTB)
Number of subjects: 43
Study 31821294 — intervention group
Group type: COMPARATOR
Intervention: Hamstring tendon autograft (GST)
Number of subjects: 43
Study 27129607 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW)
Number of subjects: 152
Study 27129607 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 152